-+ 0.00%
-+ 0.00%
-+ 0.00%

BRIEF-Acumen Pharmaceuticals Announces First Participant Dosed In Phase 2 Open-Label Extension Study Of Sabirnetug In People With Early Alzheimer’S Disease

Reuters·11/17/2025 13:01:01

Please log in to view news